Phosphatase inhibitors with anti-angiogenic effect in vitro

APMIS

Volumn 118, Issue 1, 2010, Pages 49-59

  Sylvest, Lene ^a   Bendiksen, Christine Dam ^a   Houen, Gunnar ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Angiogenesis inhibition; ELISA based screening assay; Endothelial cells; Morphology; Phosphatase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; CLODRONIC ACID; IBANDRONIC ACID; LEVAMISOLE; NSC 87877; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR 1; PROTEIN TYROSINE PHOSPHATASE INHIBITOR 2; PROTEIN TYROSINE PHOSPHATASE INHIBITOR 4; SALUBRINAL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; CELL DIFFERENTIATION; CELL ELONGATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; MORPHOLOGY; PRIORITY JOURNAL;

ALKALINE PHOSPHATASE; ANGIOGENESIS INHIBITORS; CELL PROLIFERATION; CINNAMATES; CLODRONIC ACID; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORIC MONOESTER HYDROLASES; QUINOLINES; THIOUREA;

EID: 73149103697     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02561.x     Document Type: Article

References (39)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990 82 : 4 6.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 86 : 353 64.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000 407 : 249 57.
4. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999 6 : R217 24.
5. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002 282 : C947 70.
6. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003 3 : 422 33.
7. Folkman J. Angiogenesis. Annu Rev Med 2006 57 : 1 18.
8. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004 3 : 391 400.
9. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Hematol 2009 22 : 115 28.
10. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor Bevacizumab in cancer patients: a meta analysis. JAMA 2008 300 : 2277 85.
11. Daher IN, Yeh ET. Vascular complications of selected cancer therapies. Nat Pract Cardiovasc Med 2008 5 : 797 805.
12. Friis T, Hansen AB, Houen G, Engel AM. Influence of angiogenesis inhibitors on endothelial cell morphology in vitro. APMIS 2006 114 : 211 24.
13. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 2004 30 : 379 85.
14. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006 1765 : 178 88.
15. Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Invest Drugs 2008 17 : 1717 34.
16. Zaniboni A. Suramin: the discovery of an old anticancer drug. Med Oncol Tumor Pharmacother 1990 7 : 287 90.
17. Kruger EA, Figg WD. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Invest Drugs 2000 9 : 1383 96.
18. Meric JB, Rottey S, Olaussen K, Soria JC, Khavat D, Rixe O, et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006 59 : 51 64. (Pubitemid 43903278)
19. Spikermann K, Faber F, Voswinckel R, Hiddemann W. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol 2002 30 : 767 73.
20. Friis T, Engel AM, Klein BM, Rygaard J, Houen G. Levamisole inhibits angiogenesis in vitro and tumor growth in vivo. Angiogenesis 2005 8 : 25 34.
21. Van Belle H. Alkaline phosphatase. I. Kinetics and inhibition by levamisole of purified isoenzymes from humans. Clin Chem 1976 22 : 972 6.
22. Mohi MG, Neel BG. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 2007 17 : 23 30.
23. Friis T, Kjaer SB, Engel AM, Rygaard J, Houen G. A quantitative ELISA-based co-culture angiogenesis and cell proliferation assay. APMIS 2003 111 : 658 68.
24. Ren Y, Meng S, Mei L, Zhao ZJ, Jove R, Wu J. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem 2004 279 : 8497 505.
25. Wu CJ, O'Rourke DM, Feng GS, Johnson GR, Wang Q, Greene MI. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinaseAkt activation by growth factors. Oncogene 2001 20 : 6018 25.
26. Yu DH, Qu CK, Henegariu O, Lu X, Feng GS. Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J Biol Chem 1998 273 : 21125 31.
27. Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC, et al. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol 2006 70 : 562 70.
28. Laramee M, Chabot C, Cloutier M, Stenne R, Holgado-Madruga M, Wong AJ, et al. The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation. J Biol Chem 2007 282 : 7758 69.
29. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 9 : 669 76.
30. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002 62 : 6538 44.
31. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005 307 : 935 9.
32. Cnop M, Ladriere L, Hekerman P, Ortis F, Cardozo AK, Dogusan Z, et al. Selective inhibition of eukaryotic translation initiation factor 2 alpha dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic beta-cell dysfunction and apoptosis. J Biol Chem 2007 282 : 3989 97.
33. Soeda S, Shimada T, Koyanagi S, Yokomatsub T, Muranob T, Shibuyab S, et al. An attempt to promote neo-vascularization by employing a newly synthesized inhibitor of protein tyrosine phosphatase. FEBS Lett 2002 524 : 54 8.
34. Liang F, Lee SY, Liang J, Lawrence DS, Zhang ZY. The role of protein-tyrosine phosphatase 1B in integrin signaling. J Biol Chem 2005 280 : 24857 63.
35. Wiesmann C, Barr KJ, Kung J, et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 2004 11 : 730 7.
36. Guo D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995 270 : 6729 33.
37. Huang P, Ramphal J, Wei J, Liang C, Jallal B, McMahon G, et al. Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases. Bioorg Med Chem 2003 11 : 1835 49.
38. Mannell H, Hellwig N, Gloe T, Plank C, Sohn HY, Groesser L, et al. Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo. J Vasc Res 2008 45 : 153 63.
39. Artwohl M, Holzenbein T, Wagner L, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM. Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol 2000 131 : 1577 83.